Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
List view / Grid view
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
8 September 2011 | By Roche
Roche recognized as the most sustainable healthcare company globally in the DJSI...
6 September 2011 | By Evotec AG
Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD) to be developed...
In this Genomics / Sequencing supplement: NGS powers up drug discovery and healthcare; Impact of novel sequencing technology on transcriptome analysis; Making sense of nonesense (and missense): Bringing the results of recent genetic studies into the drug discovery laboratory...
17 August 2011 | By Roche
First and only personalized medicine shown to help people with BRAF V600E mutation-positive metastatic melanoma...
4 August 2011 | By Roche
Lebrikizumab has potential to be the first personalized treatment for asthma...
3 August 2011 | By Roche
The European Commission has approved the use of RoACTEMRA (tocilizumab)...
25 July 2011 | By Roche
Roche has been awarded an exclusive contract by the National Health Laboratory Services (NHLS)...
20 July 2011 | By Merck
Merck has signed a new non-exclusive agreement with Roche...
19 July 2011 | By Roche
Roche has signed an agreement to acquire 100% of mtm laboratories AG (mtm)...
15 July 2011 | By Roche
Roche plans to seek approval with Health Authorities based on encouraging results...
24 June 2011 | By Roche
Roche and Evotec AG announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs...
23 June 2011 | By Roche
Roche announced the launch of a new R&D Institute in France...
20 June 2011 | By Roche
Pivotal Phase II study with vismodegib showed positive results in people with advanced advanced basal cell carcinoma.
5 June 2011 | By Roche
Roche announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...